Max F. Thijssen, Isabel M. A. Brüggenwirth, Andrew Gillooly, Anastasia Khvorova, Timothy F. Kowalik, Paulo N. Martins – 18 December 2018 – RNA interference (RNAi) is a natural process of posttranscriptional gene regulation that has raised a lot of attention culminating with the Nobel Prize in Medicine in 2006. RNAi‐based therapeutics have been tested in experimental transplantation to reduce ischemia/reperfusion injury (IRI) with success.

Roslin Y. Docta, Tiago Ferronha, Joseph P. Sanderson, Thomas Weissensteiner, George R. Pope, Alan D. Bennett, Nicholas J. Pumphrey, Zoltan Ferjentsik, Laura L. Quinn, Guy E. Wiedermann, Victoria E. Anderson, Manoj Saini, Miguel Maroto, Elliot Norry, Andrew B. Gerry – 18 December 2018 – Patients with hepatocellular carcinoma (HCC) have a poor prognosis and limited therapeutic options. Alpha‐fetoprotein (AFP) is often expressed at high levels in HCC and is an established clinical biomarker of the disease.

Derek Lee, Iris Ming‐Jing Xu, David Kung‐Chun Chiu, Josef Leibold, Aki Pui‐Wah Tse, Macus Hao‐Ran Bao, Vincent Wai‐Hin Yuen, Cerise Yuen‐Ki Chan, Robin Kit‐Ho Lai, Don Wai‐Ching Chin, Daniel For‐Fan Chan, Tan‐To Cheung, Siu‐Ho Chok, Chun‐Ming Wong, Scott W. Lowe, Irene Oi‐Lin Ng, Carmen Chak‐Lui Wong – 18 December 2018 – Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers worldwide which lacks effective treatment. Cancer cells experience high levels of oxidative stress due to increased generation of reactive oxygen species (ROS).

Samer Chehade, Paul C. Adams – 18 December 2018

Ju Dong Yang, Tushar Patel – 17 December 2018

Lisa Katharina Maresch, Pia Benedikt, Ursula Feiler, Sandra Eder, Kathrin A. Zierler, Ulrike Taschler, Stephanie Kolleritsch, Thomas O. Eichmann, Gabriele Schoiswohl, Christina Leopold, Beatrix I. Wieser, Caroline Lackner, Thomas Rülicke, Jan van Klinken, Dagmar Kratky, Tarek Moustafa, Gerald Hoefler, Guenter Haemmerle – 17 December 2018 – Murine hepatic carboxylesterase 2c (Ces2c) and the presumed human ortholog carboxylesterase 2 (CES2) have been implicated in the development of nonalcoholic fatty liver disease (NAFLD) in mice and obese humans.

Reenam S. Khan, Fernando Bril, Kenneth Cusi, Philip N. Newsome – 16 December 2018 – Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to become the leading cause of liver transplantation, yet there is a lack of effective licensed treatments for these conditions. There is a close relationship between insulin resistance (IR) and NAFLD, with prevalence of NAFLD being 5‐fold higher in patients with diabetes compared to those without.

Reenam S. Khan, Fernando Bril, Kenneth Cusi, Philip N. Newsome – 16 December 2018 – Nonalcoholic fatty liver disease (NAFLD) has an estimated prevalence of 25% in the general population, and cirrhosis secondary to nonalcoholic steatohepatitis (NASH) is predicted to become the leading cause of liver transplantation, yet there is a lack of effective licensed treatments for these conditions. There is a close relationship between insulin resistance (IR) and NAFLD, with prevalence of NAFLD being 5‐fold higher in patients with diabetes compared to those without.

Chih‐Lang Lin, Yu‐De Chu, Chau‐Ting Yeh – 15 December 2018

Yun‐Shan Wang, Lutao Du, Xingsi Liang, Peng Meng, Lei Bi, Yu‐li Wang, Chuanxin Wang, Bo Tang – 15 December 2018 – Sirtuin 4 (SIRT4) has been reported to play a vital role in the maintenance of glutamine catabolism and adenosine triphosphate (ATP) homeostasis, but its character in hepatocellular carcinomas (HCCs) remains obscure. In this study, we observed low expression of SIRT4 in both HCC cell lines and HCCs from patients. Decreased disease‐free survival time is associated with low tumor levels of SIRT4 in patients.